NWTraumatherapies

NWTraumatherapies is a clinical-stage biotechnology company based in Bozeman, Montana, focused on developing psychedelic-based therapies for chronic illnesses and trauma. The company is currently conducting the Northwest Therapies Trauma Psilocybin Study (NWTTPS), a Phase 1 trial evaluating the safety and efficacy of 'enhanced microdosing' using non-synthesized psilocybin. Their research targets the 5-HT2A receptor to promote neuroplasticity and regulate the nervous system in patients with conditions such as PTSD, treatment-resistant depression, and long COVID. The company's approach combines plant-based medicine with clinical oversight to address mental health challenges that standard pharmacotherapies have failed to resolve.